Powering the genetic medicine revolution
Our novel, synthetic DNA vector, “doggybone” or dbDNA™, and its enzymatic production, enable us to make DNA at the speed, scale and purity necessary to support the rapid growth of genetic medicines.
DNA made using enzymes
We are disrupting the decades-old technology of DNA production, moving away from restrictive biological approaches to instead use a synthetic DNA vector.Our platform technology
Enzymatic manufacturing enables multi-gram GMP DNA production in weeks rather than months
Manufactured using benchtop equipment with a significantly smaller footprint than fermentation-based production
dbDNA™ technology is highly portable and amenable to technology transfer
dbDNA™ can encode long, complex, unstable sequences, eliminates bacterial sequences, and has a strong expression profile
Addressing a broad market
Our versatile dbDNA™ technology is being applied across the genetic medicine industry.
What can we do for you?
We offer a range of services to support development and commercialisation of the next generation of DNA products.
- Catalogue products
- Molecular biology
- Custom research grade
- Toxicology materials
- GMP dbDNA™ (critical starting materials)
- GMP dbDNA™ (drug substance)
- Commercial supply / on-site supply
- Analytical development
- Scale up development
- Regulatory support
Headquartered in Hampton
Take a tour of our stunning buildings and state-of-the-art dbDNA™ manufacturing facilities.View our facilities
Brochure – Touchlight doggybone DNADownload
Webinar – Overcoming the challenges of plasmid DNA in AAV manufacturingRead Article
White Paper – The future of Industrial Scale Lentiviral Vector ManufacturingRead Article
Article – Antibiotics in biopharmaceutical productionRead Article
Webinar – Strategies for commercialising a novel enzymatic DNA technologyRead Article
24 January 2023
FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Drug Master File simplifies the U.S. regulatory process for utilising Touchlight’s doggybone DNA and accelerates regulatory filings. doggybone DNA is the first enzymatic DNA platform with a Drug Master File,...
07 December 2022
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy utilising doggybone DNA
Touchlight and Odimma have entered into an agreement to develop and supply clinical material for Odimma’s neoantigen program Hampton, UK, 7 December 2022 – Touchlight, a biotechnology company pioneering enzymatic...
29 November 2022
Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform
Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses....
We'd like to hear from you
For more information on how our dbDNA™ technology could help advance your project, please contact us.Get in touch